The FDA has removed a black box warning for estrogen-related hormone replacement therapy (HRT) products, which had previously included warnings for breast cancer and other indications. However, the removal of the warning has coincided with reports of a national shortage of estrogen patches. The impact of the FDA's decision on the availability of these products is uncertain, with some outlets suggesting the shortage may not be resolved soon.